Halozyme Therapeutics, Inc. $HALO Shares Sold by Hantz Financial Services Inc.

Hantz Financial Services Inc. lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 20.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,913 shares of the biopharmaceutical company’s stock after selling 20,021 shares during the quarter. Hantz Financial Services Inc.’s holdings in Halozyme Therapeutics were worth $5,244,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Swedbank AB grew its holdings in Halozyme Therapeutics by 10.1% during the 4th quarter. Swedbank AB now owns 162,062 shares of the biopharmaceutical company’s stock valued at $10,907,000 after buying an additional 14,900 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics during the 4th quarter valued at $124,031,000. Mizuho Markets Americas LLC boosted its holdings in shares of Halozyme Therapeutics by 270.8% during the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after purchasing an additional 926,526 shares during the last quarter. LSV Asset Management boosted its holdings in shares of Halozyme Therapeutics by 2.8% during the fourth quarter. LSV Asset Management now owns 1,301,055 shares of the biopharmaceutical company’s stock worth $87,561,000 after purchasing an additional 35,028 shares during the last quarter. Finally, Pzena Investment Management LLC boosted its holdings in shares of Halozyme Therapeutics by 4.2% during the fourth quarter. Pzena Investment Management LLC now owns 4,278 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 171 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $68.32 on Tuesday. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The stock has a market capitalization of $8.10 billion, a P/E ratio of 24.58, a PEG ratio of 0.28 and a beta of 0.89. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The business’s fifty day moving average price is $65.84 and its 200 day moving average price is $68.77.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter last year, the firm earned $1.11 earnings per share. The firm’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $49,322,187.20. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the completion of the transaction, the chief operating officer owned 14,366 shares in the company, valued at $974,014.80. The trade was a 58.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 120,482 shares of company stock worth $8,200,842. 2.50% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on HALO shares. Morgan Stanley decreased their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. HC Wainwright raised their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.